What is Biomeme?
Biomeme operates at the intersection of advanced molecular biology and portable hardware engineering. The company specializes in mobile solutions for CBRN biodefense and point-of-care gene expression diagnostics. By providing compact, automated PCR and isothermal laboratories, Biomeme enables the rapid identification of biodefense targets and infectious agents in field-ready environments. Their technology serves a critical function for military personnel, hazmat first responders, and medical researchers who require high-fidelity diagnostic capabilities outside of traditional laboratory settings. Through its innovative platform, the company is actively addressing systemic challenges such as antimicrobial resistance and the urgent need for enhanced pandemic preparedness.
How much funding has Biomeme raised?
Biomeme has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Biomeme
PPP
Public-Private Partnership
What's next for Biomeme?
With this late-stage capital, Biomeme is positioned to accelerate its product roadmap and expand its footprint in the global diagnostics market. The strategic focus will likely shift toward increasing manufacturing throughput and broadening the application of its gene expression tools to meet the evolving demands of public health surveillance. As the company matures, the integration of its diagnostic hardware into broader defense and clinical workflows will be essential for maintaining its competitive advantage. Future growth will be defined by the firm's ability to scale its proprietary technology while navigating the complex regulatory landscapes inherent in medical and biodefense sectors.
See full Biomeme company page
